Exicure (XCUR) Enterprise Value (2016 - 2026)
Exicure's (XCUR) quarterly Enterprise Value came in at -$2.6 million in Q1 2026, up 75.01% YoY from -$1.5 million in Q1 2025, and up 30.49% on a QoQ basis from -$3.7 million in Q4 2025.
Exicure (XCUR) Enterprise Value (2016 - 2026) Analysis & Trends
Exicure (XCUR) has 11 years of Enterprise Value data on file, last reported at -$2.6 million in Q1 2026.
- Quarterly Enterprise Value rose 75.01% year-over-year to -$2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.6 million (up 75.01% YoY) and the FY2025 annual result came in at -$3.7 million, up 70.05% from the prior year.
- Enterprise Value rose to -$2.6 million in Q1 2026, from -$3.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$343000.0 in Q3 2024 to a low of -$26.4 million in Q1 2022.
- A 5-year average of -$7.8 million and a median of -$4.4 million in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value surged 96.33% — and 2025, when it tumbled 2746.99%.
- Tracing XCUR's Enterprise Value over 5 years: stood at -$9.8 million in 2022, then surged by 79.38% to -$2.0 million in 2023, then plunged by 520.44% to -$12.5 million in 2024, then soared by 70.05% to -$3.7 million in 2025, then soared by 30.49% to -$2.6 million in 2026.
- The last three Enterprise Value figures came in at -$2.6 million (Q1 2026), -$3.7 million (Q4 2025), and -$4.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Exicure | 8.41 Mn | 8.41 Mn | - | -1.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.60 Mn |
| Dec 31, 2025 | -3.75 Mn |
| Sep 30, 2025 | -4.44 Mn |
| Jun 30, 2025 | -7.86 Mn |
| Mar 31, 2025 | -10.42 Mn |
| Dec 31, 2024 | -12.51 Mn |
| Sep 30, 2024 | -343,000.00 |
| Jun 30, 2024 | -528,000.00 |
| Mar 31, 2024 | -366,000.00 |
| Dec 31, 2023 | -2.02 Mn |
| Sep 30, 2023 | -922,000.00 |
| Jun 30, 2023 | -2.34 Mn |
| Mar 31, 2023 | -9.96 Mn |
| Dec 31, 2022 | -9.78 Mn |
| Sep 30, 2022 | -15.65 Mn |
| Jun 30, 2022 | -22.20 Mn |
| Mar 31, 2022 | -26.38 Mn |
| Dec 31, 2021 | -39.14 Mn |
| Sep 30, 2021 | -60.84 Mn |
| Jun 30, 2021 | -56.06 Mn |